Arabian International Healthcare Holding Company(9530.SR)
No price history available.
Key financial summary
Financials in SAR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | SARm | 819 | 619 | 643 | 807 | 814 | 842 | N/A | N/A |
| Operating profit | SARm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | SARm | 96 | 82 | 20 | 38 | -67 | 24 | N/A | N/A |
| EPS reported | SAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | SAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | SAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | SAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | SARm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | SARm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | SARm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | SAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | SAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in SAR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Arabian International Healthcare Holding Company engages in distribution and maintenance of medical, devices, imaging equipment, prosthetics, dental and veterinary equipment, and cosmetic products in the Kingdom of Saudi Arabia. The company operates through three segments: Medical Devices, Medical Supplies, and Clinical & Pharmaceutical. It offers various products for cardiology, intensive care, oncology, rehab, infection prevention technologies, hospital infrastructure, gene sequencing laboratory, anesthesia machines, hospital beds and medical furniture, lab furniture solution, biobanking solution, hospital information technology, surgical rooms solutions, laboratories, and ventilation system. The company also provides its products for orthopedics, management delivery solutions, catheters and syringes, and vein thrombosis prevention. In addition, it offers medical services at clinics; and sells health and beauty related medicines. The company was founded in 1973 and is headquartered in Riyadh, Saudi Arabia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Arabian International Healthcare Holding Company (9530.SR)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Arabian International Healthcare Holding Company engages in distribution and maintenance of medical, devices, imaging equipment, prosthetics, dental and veterinary equipment, and cosmetic products in the Kingdom of Saudi Arabia. The company operates through three segments: Medical Devices, Medical Supplies, and Clinical & Pharmaceutical. It offers various products for cardiology, intensive care, oncology, rehab, infection prevention technologies, hospital infrastructure, gene sequencing laboratory, anesthesia machines, hospital beds and medical furniture, lab furniture solution, biobanking solution, hospital information technology, surgical rooms solutions, laboratories, and ventilation system. The company also provides its products for orthopedics, management delivery solutions, catheters and syringes, and vein thrombosis prevention. In addition, it offers medical services at clinics; and sells health and beauty related medicines. The company was founded in 1973 and is headquartered in Riyadh, Saudi Arabia.
